Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 115, Issue 5, Pages 1298-1305Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI200523057
Keywords
-
Categories
Funding
- Intramural NIH HHS [Z99 AA999999] Funding Source: Medline
Ask authors/readers for more resources
Endogenous cannabinoids acting at CB, receptors stimulate appetite, and CB, antagonists show promise in the treatment of obesity. CB1-/- mice are resistant to diet-induced obesity even though their caloric intake is similar to that of wild-type mice, suggesting that endocannabinoids also regulate fat metabolism. Here, we investigated the possible role of endocannabinoids in the regulation of hepatic lipogenesis. Activation of CB1 in mice increases the hepatic gene expression of the lipogenic transcription factor SR-EBP-1c and its targets acetyl-CoA carboxylase-1 and fatty acid synthase (FAS). Treatment with a CB1 agonist also increases de novo fatty acid synthesis in the liver or in isolated hepatocytes, which express CB1. High-fat diet increases hepatic levels of the endocannabinoid anandamide (arachidonoyl ethanolamide), CB1 density, and basal rates of fatty acid synthesis, and the latter is reduced by CB1 blockade. In the hypothalamus, where FAS inhibitors elicit anorexia, SREBP-1c and FAS expression are similarly affected by CB1 ligands. We conclude that anandamide acting at hepatic CBI contributes to diet-induced obesity and that the FAS pathway may be a common molecular target for central appetitive and peripheral metabolic regulation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available